Articles From: ACETO Reports Third Quarter Fiscal 2014 Financial Results to Actavis to Present at Goldman Sachs 35th Annual Global Healthcare Conference 2014


PORT WASHINGTON, N.Y., May 8, 2014 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the third quarter of fiscal 2014 ended March 31, 2014.
Sign-up for ACETO Reports Third Quarter Fiscal 2014 Financial Results investment picks
PORT WASHINGTON, N.Y., April 3, 2014 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, is launching the 10/12.5mg, 20/12.5mg and 20/25mg strengths of Benazepril/HCTZ, the authorized generic of Validus' Lotensin HCT ® .
Sign-up for ACETO Subsidiary, Rising Pharmaceuticals, Launches the Authorized Generic of Validus' Lotensin HCT(R) investment picks
SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO) , a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter ended March 31, 2014.
Sign-up for Achaogen Announces First Quarter 2014 Results investment picks
SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO) , a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 13 th Annual Needham Healthcare Conference in New York, New York.
Sign-up for Achaogen to Present at 13th Annual Needham Healthcare Conference investment picks
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug - NEW HAVEN, Conn., April 30, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that is has begun dosing study participants with ACH-3422, Achillion's proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial.
Sign-up for Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV investment picks
NEW HAVEN, Conn., May 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2014.
Sign-up for Achillion Reports First Quarter 2014 Financial Results investment picks
NEW HAVEN, Conn., May 1, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at three upcoming investor conferences: The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com .
Sign-up for Achillion to Present at Three Upcoming Investor Conferences investment picks
2014/5/6
http://media.marketwire.com/attachments/201302/57392_Achronixlogoresized.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1111899&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for Achronix Announces PCI-SIG(R) Compliance for Hardened PCI Express on Speedster22i FPGAs investment picks
2014/5/15
NEW YORK (MarketWatch) -- Pershing Square Capital Management, the hedge fund run by Bill Ackman, sold the remainder of its stake in Proctor & Gamble (PG) during the previous quarter, his company's 13-F filing revealed Thursday.
Sign-up for Ackman dumps remainder of P&G stake investment picks
SAN FRANCISCO (MarketWatch) -- Hedge fund manager Bill Ackman agreed to pay an Herbalife (HLF) whistleblower as much as $3.6 million if the executive lost his job with the nutritional supplements maker, ABC news reported Tuesday.
Sign-up for Ackman paid Herbalife whistleblower: report investment picks
2014/4/23
NEW YORK (MarketWatch) -- The poison pill put in place by the board of Allergan Inc. [s;agn] is way for the company's directors to explore other options and isn't necessarily a bad thing, activist investor William Ackman told CNBC on Wednesday.
Sign-up for Ackman: Didn't violate insider-trading rules over Allergan investment picks
SHANGHAI , May 13, 2014 /PRNewswire/ -- Acorn International, Inc. (NYSE: ATV) ("Acorn" or the "Company"), a media and branding company in China engaged in developing, promoting, and selling products through extensive direct and distribution networks, will release its financial results for the first quarter 2014 before the market opens on Tuesday, May 27, 2014 .
Sign-up for Acorn International to Announce First Quarter 2014 Financial Results on May 27, 2014 investment picks
SAN DIEGO and CHARLOTTE, N.C., May 12, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Chelsea Therapeutics International, Ltd (NASDAQ: CHTP) by the private equity firm H.
Sign-up for Acquisition Chelsea Therapeutics International, Ltd by H. Lundbeck A/S May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and MORRISVILLE, N.C. , April 28, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) by Forest Laboratories, Inc. (NYSE: FRX) .
Sign-up for Acquisition of Furiex Pharmaceuticals, Inc. by Forest Laboratories, Inc. May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and FORT WORTH, Texas , April 30, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of OmniAmerican Bancorp, Inc. (NASDAQ: OABC) by Southside Bancshares, Inc. (NASDAQ: SBSI) .
Sign-up for Acquisition of OmniAmerican Bancorp, Inc. by Southside Bancshares, Inc. May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and WASHINGTON, April 30, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Pepco Holdings, Inc. (NYSE: POM) by Exelon Corporation (NYSE: EXC) .
Sign-up for Acquisition of Pepco Holdings, Inc. by Exelon Corporation May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and PARSIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Pinnacle Foods Inc. (NYSE: PF) by Hillshire Brands Company (NYSE: HSH) .
Sign-up for Acquisition of Pinnacle Foods Inc. by Hillshire Brands Company May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and PICKERINGTON, Ohio , May 5, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of R.G. Barry Corporation (NASDAQ: DFZ) by the private equity firm Mill Road Capital.
Sign-up for Acquisition of R.G. Barry Corporation by Mill Road Capital May Not Be in Shareholders' Best Interests investment picks
2014/07/18
Moat-building cost and brand advantages position the firm well.
Sign-up for Acquisitions Are a Value-Enhancing Strategy for VF investment picks
-- Companies Schedule Shareholder Meetings for June 17, 2014 --
Sign-up for Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4 investment picks
DUBLIN , May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya ® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya ® Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris.
Sign-up for Actavis Announces Acanya® Gel Patent Challenge Settlement investment picks
DUBLIN , April 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Celebrex ® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Sign-up for Actavis Announces Celebrex® Patent Challenge Settlement investment picks
DUBLIN , April 21, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that G.
Sign-up for Actavis Announces Departure of G. Frederick Wilkinson, President, Actavis Global R&D investment picks
- Paul Bisaro to Assume Newly Created Role as Executive Chairman - - Brent Saunders to be Named CEO and President - - Robert Stewart to be Named COO - - Bill Meury to be Named EVP Commercial, North American Brands - - David Buchen to be Named EVP Commercial, North American Generics and International - DUBLIN , May 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year.
Sign-up for Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition investment picks
DUBLIN , May 7, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS ® (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the U.S. Food and Drug Administration.
Sign-up for Actavis Launches Generic Version of Catapres-TTS® investment picks
- First Quarter 2014 GAAP Earnings Per Diluted Share of $0.55 - - 86% Increase in First Quarter 2014 Adjusted EBITDA to $860 million - DUBLIN , April 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014 , compared to $1.90 billion in the first quarter 2013.
Sign-up for Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014; Non-GAAP EPS Increases 75% to $3.49 investment picks
DUBLIN , May 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition") of Forest Laboratories, Inc. (NYSE: FRX) , it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Sign-up for Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations investment picks
DUBLIN , May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo ® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity.
Sign-up for Actavis Receives Final Approval for Generic Version of Exalgo® investment picks
DUBLIN , April 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex ® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Sign-up for Actavis Sues FDA Regarding Delay of Generic Celebrex® Approval investment picks
DUBLIN , May 21, 2014 /PRNewswire/ -- Actavis plc (NYSE:ACT) , a leading global specialty pharmaceutical company, today announced that Paul Bisaro , Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs 35 th Annual Global Healthcare Conference 2014 in Rancho Palos Verdes, California .
Sign-up for Actavis to Present at Goldman Sachs 35th Annual Global Healthcare Conference 2014 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ACETO Reports Third Quarter Fiscal 2014 Financial Results to Actavis to Present at Goldman Sachs 35th Annual Global Healthcare Conference 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry